Duits, Flora H.
Brinkmalm, Gunnar
Teunissen, Charlotte E.
Brinkmalm, Ann
Scheltens, Philip
Van der Flier, Wiesje M.
Zetterberg, Henrik
Blennow, Kaj
Funding for this research was provided by:
Alzheimer Nederland (WE.15-2013-08)
Swedish research council
European Research Council
Åhlén-stiftelsen
Swedish state support for clinical research
Hjärnfonden
Swedish alzheimer foundation
Knut och Alice Wallenbergs Stiftelse
Torsten Söderbergs Stiftelse
Frimurarestiftelsen
Stiftelsen för Gamla Tjänarinnor
Gun och Bertil Stohnes Stiftelse
Magnus Bergvalls Stiftelse
Stichting Dioraphte
Article History
Received: 9 November 2017
Accepted: 20 December 2017
First Online: 15 January 2018
Ethics approval and consent to participate
: All subjects in this study gave written informed consent for the use of their clinical data and CSF for research purposes. The study was approved by the local ethical review board.
: Not applicable.
: None of the sponsors had any role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, and approval of the manuscript; or in the decision to submit the manuscript for publication. CET is a member of international advisory boards of Fujirebio and Roche and has performed contract research for Probiodrug, IBL, and Shire. PS serves or has served on the advisory boards of Novartis, Pfizer, Roche, Danone, Janssen Alzheimer Immunotherapy, Baxter, and Lundbeck. PS also has been a speaker at symposia organized by Lundbeck, Eli Lilly and Company, Merz Pharma, Pfizer, Janssen Alzheimer Immunotherapy, Danone, and Roche. PS is co-editor-in-chief of Alzheimer’s Research & Therapy. PS also is a member of the scientific advisory board of the EU Joint Programme on Neurodegenerative Disease Research (JPND) and the French National Plan Alzheimer. In addition, PS acts as vice-chair of the Dutch Deltaplan for Dementia. PS receives no personal compensation for the activities mentioned above. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.